OncoMatch/Clinical Trials/NCT05334693

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Is NCT05334693 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Expanded haploidentical NK cells for acute myeloid leukemia.

Phase 1/2RecruitingBelarusian Research Center for Pediatric Oncology, Hematology and ImmunologyNCT05334693Data as of Jun 2026

Treatment: Expanded haploidentical NK cells — The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Expanded haploidentical NK cells

Cancer type

Acute Myeloid Leukemia

Demographics

Ages 0–21

Lab requirements

Liver function

sgot or scpt <5x upper limit of normal for age

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05334693 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 21 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Acute Myeloid Leukemia trials